Abcellera Biologics Inc (ABCL) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.63 (-0.79%), Market cap $1.40B, 52-week low–high $1.97 ~ $6.17.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was
Financial statements, price targets, institutional (13F) holdings and related news for Abcellera Biologics Inc are updated in real time on BlackAll Trade.
Abcellera Biologics Inc trades at $12.63 (-0.79%). Real-time quotes and charts are available on BlackAll Trade.
Abcellera Biologics Inc has a market cap of about $1.40B.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medic